Mesoblast (NASDAQ:MESO) Shares Down 4% - What's Next?

Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) were down 4% during trading on Monday . The company traded as low as $14.91 and last traded at $15.00. Approximately 56,464 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 285,049 shares. The stock had previously closed at $15.62.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MESO. Jefferies Financial Group cut shares of Mesoblast from a "buy" rating to a "hold" rating in a research note on Friday. Cantor Fitzgerald raised shares of Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Mesoblast Price Performance

The business's 50-day simple moving average is $11.32 and its two-hundred day simple moving average is $13.50. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 0.22.

Institutional Investors Weigh In On Mesoblast

Hedge funds have recently made changes to their positions in the business. Barclays PLC bought a new stake in Mesoblast in the 4th quarter worth approximately $38,000. JPMorgan Chase & Co. bought a new stake in Mesoblast in the fourth quarter valued at approximately $50,000. BNP Paribas Financial Markets lifted its position in Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock valued at $51,000 after purchasing an additional 2,597 shares during the last quarter. Advisors Preferred LLC lifted its position in Mesoblast by 224.9% in the first quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock valued at $54,000 after purchasing an additional 3,169 shares during the last quarter. Finally, Tower Research Capital LLC TRC bought a new stake in Mesoblast in the fourth quarter valued at approximately $88,000. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.